Prospective intervention study of novel SGLT-2 inhibitor ipragliflozin in patients with type 2 diabetes
Phase of Trial: Phase III
Latest Information Update: 29 Dec 2017
Price : $35 *
At a glance
- Drugs Ipragliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 25 Dec 2017 Status changed from active, no longer recruiting to completed.
- 12 Apr 2016 Status changed from recruiting to active, no longer recruiting.
- 25 Aug 2015 Status changed from not yet recruiting to recruiting, as reported by University Hospital Medical Information Network - Japan